Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 03 - 15 tags : Disease save search
Institute for Molecular Medicine Receives $12 Million NIH Grant to Fund Clinical Trials of AV-1959, First Preventive Vaccine for Alzheimer's Disease
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
FNCTF | News | $11.0354 34K
|
Communications
|
| O: 0.71%
H: 0.0%
C: 0.0%
av-1959 alzheimer als fun 2 million trials trial disease clinical trials molecular vaccine grant alzheimer’s alzheimer's disease alzheimer's
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
GANX | $3.24 1.89% 35K
|
Professional, Scientific, and T...
|
| O: 9.7%
H: 2.76%
C: -7.46%
alzheimer pos parkinson conference therapeutics disease positive alzheimer’s alzheimer's disease alzheimer's
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
INMB | $8.65 2.61% 18K
|
Health Technology
|
| O: 0.0%
H: 2.98%
C: -4.46%
alzheimer parkinson conference presentation disease international tiona alzheimer’s alzheimer's
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
Published: 2022-03-15 (Crawled : 13:30) - prnewswire.com
SNPX | $4.89 1.88% 9.6K
|
Professional, Scientific, and T...
|
| O: 0.92%
H: 7.12%
C: -2.15%
alzheimer parkinson research conference disease potential international tiona alzheimer’s bryostatin alzheimer's
Lyfebulb and CVS Kidney Care® Announce Finalists for 2022 Innovation Challenge in Kidney Disease
Published: 2022-03-15 (Crawled : 13:00) - prnewswire.com
CVS | $69.26 0.96% 2.1M
|
Retail Trade
|
| O: 0.49%
H: 2.33%
C: 1.89%
care kidney disease
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
AVXL | $4.065 -0.12% 270K
|
Health Technology
|
| O: 0.4%
H: 6.32%
C: 5.24%
pdd-001 anavex phase 2 dementia anavex®2-73 parkinson conference presentation disease life science international tiona biomarkers
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
Published: 2022-03-15 (Crawled : 12:00) - biospace.com/
SAGE | News | $13.46 7.08% 610K
|
Health Technology
|
| O: 1.07%
H: 2.93%
C: 1.06%
sage-718 phase 2 air parkinson therapeutics presentation disease results
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
HOLO | $2.86 27.68% 28M
|
XPON | $2.43 25.91% 7.2M
|
Your saved searches
Save your searches and get alerts when important news are released.